BLACK WEEKSInjektiopullot −15 % · kitit −10 % · muut −5 %koodillaIlmainen toimitus Saksaan alk. €200

Tämä sivu on käännetty automaattisesti, ja siinä voi olla virheitä. Onko suomi äidinkielesi? Otamme mielellämme vastaan palautetta ja korjauksia.Lähetä palautetta

The Peptide Desk The Peptide Desk
Empagliflozin (Jardiance), tuotekuva
Medication

Empagliflozin (Jardiance)

Medication

  • Lähetetään Saksasta

Tilaus

Kappalehinta - Ilmainen toimitus Saksaan yli 200 €:n tilauksille Black Weeksin aikana
  • DHL seurannalla
  • Huomaamaton pakkaus

4.6/5 Trustpilotissa73 arvostelua

Yhdellä silmäyksellä

Empagliflozin (Jardiance) lukuina

Tietopankkimme keskeiset luvut. Vedä pistettä käyrää pitkin nähdäksesi, paljonko yhden annoksen jälkeen on laskennallisesti jäljellä.

Koko tietopankkiartikkeli

How long does it stay in the body?

Share left after one dose, calculated with a half-life of ~12 hours

Half-life ~12 hours
After 24 hours: 25 %
Hour 1250 %Hour 2425 %Hour 3612.5 %Hour 603.1 %

Simplified model without an absorption phase, half-life from the TPD lexicon.

Half-life

about12hours

effect lasts 24h

Class
SGLT2 inhibitorselective, oral
Use
Oralonce daily in the morning
Sizes
10 to 25 mg2 sizes in the shop

Tuotteelle Empagliflozin (Jardiance) ei ole vielä laboratorioanalyysia. Äänestä sitäTestauta itse, me maksamme puoletKaikki laboratorioanalyysit

Tietoa

Kaikki aiheesta Empagliflozin (Jardiance)

FAQ

Usein kysyttyä

Lähteet jokaiseen vastaukseen: tietopankkiartikkeli

Onko sinulla vielä kysyttävää?

Kirjoita meille, tiimimme auttaa sinua.

Is empagliflozin approved?

Yes. In the USA it has been marketed as a prescription drug since 1 August 2014. According to the label for type 2 diabetes, to reduce cardiovascular death in diabetes with cardiovascular disease and in heart failure. It is not recommended in type 1 diabetes because of the ketoacidosis risk.

How does empagliflozin work?

It blocks SGLT2 in the kidney, the transporter that takes sugar back from the urine. In a cell assay a concentration of 3.1 nM was enough for half-maximal inhibition. Of all inhibitors tested it was the most selective over the gut transporter SGLT1. The sugar is lost with the urine, independently of insulin.

What did EMPA-REG OUTCOME show?

7,020 people with type 2 diabetes and cardiovascular disease were followed for a median of 3.1 years. The primary outcome of cardiovascular death, heart attack and stroke fell from 12.1 to 10.5 percent. Cardiovascular deaths fell by 38 percent, hospitalisations for heart failure by 35 percent and deaths from any cause by 32 percent. Heart attack and stroke did not differ significantly.

Does it also work without diabetes?

In heart failure, yes. In EMPEROR-Reduced and EMPEROR-Preserved the effect was the same with and without diabetes, likewise in chronic kidney disease in EMPA-KIDNEY. With reduced ejection fraction kidney function fell by 0.55 instead of 2.28 ml per minute per year.

What is euglycaemic ketoacidosis?

Acidification of the blood by ketone bodies while blood sugar is normal or only slightly raised. On SGLT2 inhibitors the typical warning sign of high sugar is therefore missing. The medical literature describes it as a predictable, detectable and preventable risk of the drug class.

Which side effects have been described?

In EMPA-REG OUTCOME only genital infections were more common than on placebo. In EMPEROR-Reduced uncomplicated genital infections were more common, in EMPEROR-Preserved also urinary tract infections and low blood pressure. In EMPA-KIDNEY serious adverse events were equally common in both groups.

Liittyvät

Samankaltaiset tuotteet